ESC 365 - TWILIGHT-HBR: Ticagrelor Monotherapy in High Bleeding Risk Patients

ESC Premium Access

TWILIGHT-HBR: Ticagrelor Monotherapy in High Bleeding Risk Patients

Session: Trial Updates in ACS & PCI

Topic: Antiplatelet Drugs

Speaker: Doctor D. Cao (Milan, IT)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Doctor Davide Cao

Humanitas University, Milan (Italy)

2 presentations

0 follower

2 more presentations in this session

Antiplatelet therapy in high bleeding risk patients with and without oral anticoagulant therapy after coronary stenting

Speaker: Doctor P. Smits (Rotterdam, NL)

SYNTAX II trial: five year follow-up

Speaker: Professor A. Banning (Oxford, GB)

Access the full session

Trial Updates in ACS & PCI

Speakers: Doctor D. Cao, Doctor P. Smits, Professor A. Banning

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources